A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Century Therapeutics, Inc.
- Study ID
- NCT05768269
- Status
- Recruiting
Conditions
- Hematological Malignancy
- Solid Tumor Malignancy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- No Intervention — OTHERAs this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
Study Details
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.
Key Dates
- Start date
- Apr 29, 2024
- Status verified
- Jun 2025
- Primary completion
- Mar 31, 2040
- Completion
- Mar 31, 2040
Study Design
- Enrollment
- 375 participants (estimated)
Arms
- Arm: Cellular TherapyParticipants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
Primary Outcome Measure
Number of Participants With any Adverse Events of Special Interest (AESI) [ Time Frame: Up to 180 months ]
Central Contacts
- Century Therapeutics Clinical Team8885067670
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Dr Matthew Ulrickson 480-256-6444 |
| University of Southern California - Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Dr Yaghmour 323-865-3170 |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | |
| Corewell Health | Grand Rapids | Michigan | 49503 | |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | Dr Moyo 980-442-2301 |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45229 | Dr Latif 513-584-7824 |
| Swedish Cancer Institute | Seattle | Washington | 98104 |
Find similar trials in Gilbert, AZ
Related Studies
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibPHASE2 · Recruiting · Henry Ford Health System · Detroit, Michigan
- Membrane Target Detection for Leukemia TreatmentRecruiting · University of Missouri-Columbia · Columbia, Missouri
- Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological MalignancesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaPHASE2 · Recruiting · West Virginia University · Morgantown, West Virginia